πŸ‡ΊπŸ‡Έ FDA
Patent

US 8202990

Polo-like kinase inhibitors

granted A61PA61P1/04A61P11/00

Quick answer

US patent 8202990 (Polo-like kinase inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 19 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61P, A61P1/04, A61P11/00, A61P13/00, A61P13/12